Functional imaging of the bowel

Abdominal Imaging

Volumn 38, Issue 6, 2013, Pages 1203-1213

  Griffin, Nyree ^a   Goh, Vicky ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Colorectal cancer; CT; Diffusion weighted MRI; Dynamic contrast enhanced MRI; FDG PET CT; Inflammatory bowel disease

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 DEOXY 3 FLUOROROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; CAPECITABINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; OXALIPLATIN; RALTITREXED; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DIGESTIVE SYSTEM CANCER; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; ENTERITIS; ENTEROPATHY; HUMAN; IMAGING SYSTEM; INTESTINE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM CANCER;

CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INTESTINAL DISEASES; RADIOPHARMACEUTICALS;

EID: 84890128413     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-013-0030-8     Document Type: Article

References (83)

1. Cohade C, Osman M, Leal J, Wahl RL (2003) Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44:1797-1803
2. Kumar R, Halanaik D, Malhotra A (2010) Clinical applications of positron emission tomography-computed tomography in oncology. Indian J Cancer 47:100-119
3. Davey K, Heriot AG, Mackay J, et al. (2009) The impact of 18-fluroodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 51:997-1003
4. Gearhart SL, Frassica D, Rosen R, et al. (2006) Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 13:397-404
5. Park IJ, Kim HC, Yu CS, et al. (2006) Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 32:941-947
6. Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, et al. (2007) Fluorine 18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nuc Med Mol Imaging 34:859-867
7. Wiering B, Krabbe PF, Jager GJ, Oyen WJG, Ruers TJ (2005) The impact of fluoro-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104:2658-2670
8. Kong G, Jackson C, Koh DM, et al. (2008) The use of 18F-FDG PET/CT in colorectal liver metastases - comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35:1323-1329
9. Capirci C, Rampin L, Erba PA, et al. (2007) Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nuc Med Mol Imaging 34:1583-1593
10. Calvo FA, Domper M, Matute R, et al. (2004) 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58:528-535
11. Kubota R, Yamada S, Kubota K, et al. (1992) Intratumoural distribution of fluorine-18-fllruodeoxyglocose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972-1980
12. Amthauer H, Denecke T, Rau B, et al. (2004) Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31:811-819
13. Huebner RH, Park KC, Shepherd JE, et al. (2000) A meta-analysis of the literature for whole body FDG PET detection of colorectal cancer. J Nucl Med 41:1177-1189
14. Selzner M, Hany TF, Wildbrett P, et al. (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240:1027-1036
15. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC (2007) (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 13:5025-5029
16. Bassi MC, Turri L, Sacchetti G, et al. (2008) FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 70:1423-1426
17. Mees G, Dierckx R, Vangestel C, Van de Wiele C (2009) Molecular imaging of hypoxia with radiolabeled agents. Eur J Nucl Med Mol Imaging 36:1674-1686
18. Roels S, Slagmolen P, Nuyts J, et al. (2008) Biological image guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol 47:1237-1248
19. Francis DL, Freeman A, Visvikis D, et al. (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52:1602-1606
20. Bettenworth D, Reuter S, Hermann S, et al. (2013) Translational 18F-FDG PET/CT imaging to monitor lesion activity in intestinal inflammation. J Nucl Med 54:748-755
21. Lenze F, Wessling J, Bremer J, et al. (2012) Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis 18:2252-2260
22. Shyn PB (2012) 18F-FDG positron emission tomography: potential utility in the assessment of Crohn's disease. Abdom Imaging 37:377-386
23. Shyn PB, Mortele KJ, Britz-Cunningham SH, et al. (2010) Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. J Nucl Med. 51:1841-1848
24. Groshar D, Bernstine H, Stern D, et al. (2010) PET/CT enterography in Crohn disease: correlation of disease activity on CT enterography with 18F-FDG uptake. J Nucl Med 51:1009-1014
25. Jacene HA, Ginsburg P, Kwon J, et al. (2009) Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med 50:1751-1759
26. Meisner RS, Spier BJ, Einarsson S, et al. (2007) Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13:993-1000
27. Miles KA, Lee TY, Goh V, et al. (2012) Current status of dynamic contrast enhanced-computed tomography for the assessment of tumour vascular support. Eur Radiol 22:1430-1441
28. Leach MO, Morgan B, Tofts PS, et al. (2012) Imaging vascular function for early stage clinical trials using dynamic contrast enhanced MRI. Eur Radiol 22:1451-1464
29. Kut C, Mac Gabhann F, Popel AS (2007) Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97:978-985
30. Zheng S, Han MY, Xiao ZX, Peng J-P, Dong Q (2003) Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 9:1227-1230
31. Staton CA, Chetwood ASA, Cameron IC, et al. (2007) The angiogenic switch occurs at the adenoma stage of the adenoma-carcinoma sequence in colorectal cancer. Gut 56:1426-1432
32. Danese S, Sans M, de la Motte C, et al. (2006) Angiogenesis as a novel componentof inflammatory bowel disease pathogenesis. Gastroenterology 130:2060-2073
33. Scaldaferri F, Vetrano S, Sans M, et al. (2009) VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136:585-595
34. Goh V, Halligan S, Daley F, et al. (2008) Colorectal tumor vascularity: quantitative assessment with multidetector CT - do tumor perfusion measurements reflect angiogenesis? Radiology 249:510-517
35. Goh V, Rodriguez-Justo M, Engledow A, et al. (2012) Assessment of the metabolic-flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method. Eur Radiol. 22:1871-1880
36. George ML, Dzik-Jurasz AS, Padhani AR, et al. (2001) Non invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 88:1628-1636
37. Dighe S, Blake H, Jeyadevan N, et al. (2013) Perfusion CT vascular parameters do not correlate with immnohistochemically derived microvessel density count in colorectal tumors. Radiology 268:400-410
38. Bellomi M, Petralia G, Sonzogni A, et al. (2007) CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 244:486-493
39. Li Z-P, Meng Q-F, Sun C-H, et al. (2005) Tumor angiogenesis and dynamic CT in colorectal carcinoma: Radiologic-pathologic correlation. World J Gastroenterol 11:1287-1291
40. Feng S-T, Sun C-H, Li Z-P, et al. (2010) Evaluation of angiogenesis in colorectal carcinoma with multidetector CT multislice perfusion imaging. Eur J Radiol 75:191-196
41. Atkin G, Taylor NJ, Daley FM, et al. (2006) Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. Br J Surg 93:992-1000
42. Taylor SA, Punwani S, Rodriguez-Justo M, et al. (2009) Mural Crohn's disease: correlation of dynamic contrast enhanced MR imaging findings with angiogenesis and inflammation at histologic examination. Radiology 251:369-379
43. de Vries AF, Griebel J, Kremser C, et al. (2000) Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. Radiology 217:385-391
44. Sahani DV, Kalva SP, Hamberg LM, et al. (2005) Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234:785-792
45. de Lussanet QG, Backes WH, Griffoen AW, et al. (2005) Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63:1309-1315
46. De Milito A, Fais S (2005) Tumor acidity, chemoresistance and proton pump inhibitors. Fut Oncol 1:779-786
47. Torricelli P, Pecchi A, Luppi G, et al. (2003) Gadolinium-enhanced MRI with dynamic evaluation in diagnosing the local recurrence of rectal cancer. Abdom Imaging 28:19-27
48. Ziech ML, Lavini C, Caan MW, et al. (2012) Dynamic contrast-enhanced MRI in patients with luminal Crohn's disease. Eur J Radiol 81:3019-3027
49. Pupillo VA, Di Cesare E, Frieri G, et al. (2007) Assessment of inflammatory activity in Crohn's disease by means of dynamic contrast-enhanced MRI. Radiol Med 112:798-809
50. Florie J, Wasser MN, Arts-Cieslik K, et al. (2006) Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR Am J Roentgenol 186:1384-1392
51. deSouza NM, Riches SF, Vanas NJ, et al. (2008) Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 63:774-782
52. Curvo-Semedo L, Lambregts DMJ, Maas M, et al. (2012) Diffusion weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Mag Res Imaging 35:1365-1371
53. Gu J, Khong P-L, Wang S, et al. (2011) Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol 13:1020-1028
54. Mizukami Y, Ueda S, Mizumoto A, et al. (2011) Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg 35:895-899
55. Lambregts DMJ, Maas M, Riedl RG, et al. (2011) Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer - a per lesion validation study. Eur Radiol 21:265-273
56. Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47-66
57. DeVries AF, Kremser C, Hein PA, et al. (2003) Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56:958-965
58. Hein PA, Kremser C, Judmaier W, et al. (2003) Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 45:214-222
59. Kim SH, Lee JM, Hong SH, et al. (2009) Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 253:116-125
60. Sun YS, Zhang XP, Tang L, et al. (2010) Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 254:170-178
61. Lambrecht M, Deroose C, Roels S, et al. (2010) The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol 49:956-963
62. Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894-900
63. Padhani AR, Liu G, Koh DM, et al. (2009) Diffusion weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102-125
64. Patterson DM, Padhani AR, Collins DJ (2008) Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 5:220-233
65. Ono K, Ochiai R, Yoshida T, et al. (2009) Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro- 2-deoxy-d-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 29:336-340
66. Takahara T, Imai Y, Yamashita T, et al. (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275-282
67. Lambregts D, Maas M, Cappendijk V, et al. (2010) Whole body diffusion weighted imaging for distant staging in colorectal cancer: feasibility and future challenges. Ann Oncol 21:i22 ((abstract))
68. Kiryu S, Dodanuki K, Takao H (2009) Free-breathing diffusion weighted imaging for the assessment of inflammatory activity in Crohn's disease. J Magn Reson Imaging 29:880-886
69. Oto A, Zhu F, Kulkarni K, et al. (2009) Evaluation of diffusion weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease. Acad Radiol 16:597-603
70. Neubauer H, Pabst T, Dick A, et al. (2013) Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI. Pediatr Radiol. 43:103-114
71. Buisson A, Joubert A, Montoriol PF, et al. (2013) Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn's disease. Aliment Pharmacol Ther 37:537-545
72. Oussalah A, Laurent V, Bruot O, et al. (2010) Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 59:1056-1065
73. Oto A, Kayhan A, Williams JTB, et al. (2011) Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging 33:615-624
74. Tzika AA, Astrakas LG, Zarifi MK, et al. (2004) Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer 100:1246-1256
75. Cunningham CH, Vigneron DB, Marjanska M, et al. (2005) Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 53:1033-1039
76. Heerschap A, Jager GJ, van der Graaf M, et al. (1997) In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anti-cancer Res 17:1455-1460
77. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB (2002) Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 16:451-463
78. Kim MJ, Lee SJ, Lee JH, et al. (2012) Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy. Magn Reson Imaging 30:848-853
79. Bezabeh T, Somorjai RL, Smith IC, et al. (2001) The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. Am J Gastroenterol 96:442-448
80. Guillem JG, Moore HG, Akhurst T, et al. (2004) Sequential preoperative FDG-PET assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199:1-7
81. Cascini GL, Avallone A, Delrio P, et al. (2006) 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advancecd rectal cancer. J Nucl Med 47:1241-1248
82. Janssen MH, Ollers MC, Riedl RG, et al. (2010) Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-FDG PET/CT. Int J Radiat Oncol Biol Phys Med 77:392-399
83. Avallone A, Aloj L, Caracò C, et al. (2012) Early FDG PET response assessment of preoperative radiochemotherapy in locally advancecd rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging 39:1848-1857